| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $792.1M | -36.8% |
| Cost of Revenue | $733.1M | -40.5% |
| R&D Expense | $40.7M | -34.2% |
| SG&A Expense | $137.6M | -5.7% |
| Operating Income | -$258.8M | +41.7% |
| Pre-tax Income | -$338.4M | +30.4% |
| Income Tax | $1.2M | -11.4% |
| Net Income | -$339.6M | +30.3% |
| EPS (Basic) | -$0.49 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $216.4M | -18.0% |
| Accounts Receivable | $32.3M | -15.5% |
| Inventory | $12.2M | -40.3% |
| Current Assets | $332.1M | -23.5% |
| Total Assets | $1.16B | -12.0% |
| Current Liabilities | $917.3M | +1.1% |
| Long-term Debt | $761.3M | +23.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$77.9M | +88.3% |
| Capital Expenditures | $122.8M | +508.9% |
| Investing Cash Flow | -$46.7M | -214.2% |
| Financing Cash Flow | $78.7M | -73.9% |
| Free Cash Flow | -$200.7M | +70.7% |
| +86.7% |
| EPS (Diluted) | -$0.49 | +86.7% |
| Total Liabilities |
| $1.35B |
| +11.4% |
| Stockholders' Equity | -$202.1M | -307.5% |